Nov 15
|
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
|
Nov 11
|
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
|
Nov 10
|
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
|
Oct 9
|
High Growth Tech Stocks To Watch In October 2024
|
Oct 2
|
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
|
Oct 1
|
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
|
Sep 30
|
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
|
Jul 24
|
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
Jun 12
|
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
|
Jun 10
|
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
|
Jun 6
|
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
|
May 8
|
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
|
May 8
|
Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 7
|
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
|
May 7
|
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
Apr 24
|
Madrigal Statement on the Passing of Dr. Stephen Harrison
|
Apr 23
|
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
|
Apr 15
|
Latest Insider Selling in April 2024: 10 Stocks to Watch
|
Apr 9
|
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
|